Table 2.

Treatment-related adverse effects occurring in ⩾10% of patients, by treatment group (SS).

Preferred term, n (%)	1 mg/kg Q3W		3 mg/kg Q3W		10 mg/kg Q3W		200 mg Q3W		All patients
	n = 6		n = 8		n = 6		n = 10		n = 30
	Any grade	Grade ⩾3	Any grade	Grade ⩾3	Any grade	Grade ⩾3	Any grade	Grade ⩾3	Any grade	Grade ⩾3
Total	6 (100.0)	1 (16.7)	8 (100.0)	3 (37.5)	5 (83.3)	2(33.3)	9 (90.0)	4 (40.0)	28 (93.9)	10 (33.3)
Proteinuria	2 (33.3)	0	3 (37.5)	0	4 (66.7)	0	3 (30.0)	0	12 (40.0)	0
Fatigue	0	0	5 (62.5)	0	4 (66.7)	0	2 (20.0)	0	11 (36.7)	0
Fever	4 (66.7)	0	3 (37.5)	0	1 (16.7)	0	0	0	8 (26.7)	0
Weight loss	1 (16.7)	0	1 (12.5)	0S	3 (50.0)	0	3 (30.0)	0	8 (26.7)	0
Aspartate aminotransferase increased	0	0	2 (25.0)	0	3 (50.0)	0	3 (30.0)	0	8 (26.7)	0
Rash	2 (33.3)	0	4 (50.0)	0	0	0	1 (10.0)	0	7 (23.3)	0
Anorexia	2 (33.3)	1 (16.7)	1 (12.5)	0	1 (16.7)	0	2 (20.0)	1 (10.0)	6 (20.0)	2 (6.7)
White blood cell decreased	0	0	1 (12.5)	0	1 (16.7)	0	3 (30.0)	0	5 (16.7)	0
Alanine aminotransferase increased	0	0	2 (25.0)	0	2 (33.3)	0	1 (10.0)	0	5 (16.7)	0
Blood bilirubin increased	0	0	2 (25.0)	0	1 (16.7)	0	2 (20.0)	0	5 (16.7)	0
Sinus tachycardia	0	0	1 (12.5)	0	2 (33.3)	0	1 (10.0)	0	4 (13.3)	0
Hematuria	0	0	1 (12.5)	0	2 (33.3)	0	1 (10.0)	0	4 (13.3)	0
Free triiodothyronine decreased	1 (16.7)	0	1 (12.5)	0	2 (33.3)	0	0	0	4 (13.3)	0
Neutrophil count decreased	0	0	1 (12.5)	0	1 (16.7)	1 (16.7)	2 (20.0)	0	4 (13.3)	1 (3.3)
Hypokalemia	1 (16.7)	0	0	0	0	0	2 (20.0)	1 (10.0)	3 (10.0)	1 (3.3)
Nausea	0	0	0	0	2 (33.3)	0	1 (10.0)	0	3 (10.0)	0
Dyspnea	0	0	1 (12.5)	1 (12.5)	1 (16.7)	0	1 (10.0)	1 (10.0)	3 (10.0)	2 (6.7)
Anemia	1 (16.7)	1 (16.7)	0	0	0	0	2 (20.0)	0	3 (10.0)	1 (3.3)
Gastrointestinal bleeding	1 (16.7)	0	0	0	1 (16.7)	1 (16.7)	1 (10.0)	1 (10.0)	3 (10.0)	2 (6.7)
Blood thyroid stimulating hormone increased	1 (16.7)	0	0	0	1 (16.7)	0	1 (10.0)	0	3 (10.0)	0
Free thyroxine decreased	0	0	1 (12.5)	0	1 (16.7)	0	1 (10.0)	0	3 (10.0)	0

SS, safety set; n, number of patients; Q3W, every three weeks; SS.